COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01599884
Recruitment Status : Unknown
Verified May 2012 by Dennis Niewoehner, Minnesota Veterans Medical Research and Education Foundation.
Recruitment status was:  Not yet recruiting
First Posted : May 16, 2012
Last Update Posted : May 16, 2012
Information provided by (Responsible Party):
Dennis Niewoehner, Minnesota Veterans Medical Research and Education Foundation

Brief Summary:
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive pulmonary disease (COPD), particularly for those who have accompanying symptoms of chronic cough and sputum production. Randomized, placebo controlled indicate that it is safe and that it may have some clinical benefit when used at relatively low doses. It is postulated that substantially higher doses of NAC will be well-tolerated and will provide better symptom control while also decreasing blood makers of oxidant stress and inflammation.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Chronic Bronchitis Drug: N-acetylcysteine Drug: Oral acetylcysteine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1
Study Start Date : June 2012
Estimated Primary Completion Date : May 2013
Estimated Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: N-acetylcysteine
N-acetylcysteine, 1800 mg twice daily
Drug: N-acetylcysteine
1800 mg twice daily for 8 weeks

Placebo Comparator: Sugar pill
Identical to active drug
Drug: Oral acetylcysteine
Identical placebo pills twice daily for 8 weeks

Primary Outcome Measures :
  1. Changes in the St. George's Respiratory Questionnaire [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Inclusion Criteria

    • Capability to provide written informed consent
    • Age ≥ 40 years and ≤ 85 years
    • FEV1/FVC ratio (post bronchodilator) < 70%
    • FEV1 (post bronchodilator) < 65%
    • Presence of chronic cough and sputum production defined as the following:
  • Presence of chronic cough and sputum will be defined by responses to the first two questions on the SGRQ (see Appendix A). Subjects who respond positively to both question 1 (cough) and question 2 (sputum) on the SGRQ as either "several days per week" or "almost every day" will be eligible

    • Current or former smoker with lifetime cigarette consumption of at least 10 pack-years
    • Negative serum pregnancy test at the baseline visit if patient is a pre-menopausal female (menopause defined as absence of a menstrual cycle in the last 12 months)
    • Must be fluent in speaking the English language
  • Exclusion Criteria

    • Not fully recovered for at least 30 days from a COPD exacerbation characterized by typical symptoms and treated with antibiotics or prednisone
    • Known allergy or sensitivity to NAC or albuterol
    • Any patient with unstable cardiac disease
    • Any patient with a documented history of uncompensated congestive heart failure in the last 2 years
    • Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1 antitrypsin deficiency
    • Active lung cancer or history of lung cancer if it has been less than 2 years since lung resection or other treatment. If history of lung cancer, must have no evidence of recurrence in the 2 years preceding the baseline visit.
    • Undergoing active treatment for malignancy except for hormonal therapy (i.e. prostate cancer, breast cancer) or non-metastatic skin cancer and are not symptomatic
    • Chronic kidney disease with an estimated GFR of < 30 ml/min. GFR will be estimated using the Modification of Diet in Renal Disease (MDRD) formula
    • History of cirrhosis with evidence of portal hypertension (ascites, chronic edema)
    • Participation in a pulmonary rehabilitation program or completion within past 6 weeks
    • Prisoners or institutionalized patients
    • Participation in another study involving an investigational product within 30 days of the baseline visit
    • Pregnant or breast-feeding patients.
    • Use of guaifenesin in the last 30 days
    • Currently on long acting nitrates for angina or heart failure
    • Abnormalities in screening blood work defined as:
  • WBC < 3.0 or > 15.0 K/cmm
  • Hemoglobin < 9.0 or > 17.0 gm/dl
  • Platelets < 75 or > 400 K/cmm
  • ALT > 3 times the upper limit of normal
  • INR > 1.5 unless on warfarin therapy o Any concomitant condition that might endanger the patient through participation in the study or interfere with study procedures, as assessed by the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01599884

Layout table for location contacts
Contact: Dennis Niewoehner 612-467-4412

Layout table for location information
United States, Minnesota
Minneapolis VA Health Care System
Minneapolis, Minnesota, United States, 55417
Contact: Dennis Niewoehner, MD    612-467-4412      
Sponsors and Collaborators
Minnesota Veterans Medical Research and Education Foundation
Layout table for investigator information
Principal Investigator: Dennis Niewoehner, MD Minneapolis Veterans Affairs Medical Center

Layout table for additonal information
Responsible Party: Dennis Niewoehner, Staff physician, Minnesota Veterans Medical Research and Education Foundation Identifier: NCT01599884    
Obsolete Identifiers: NCT01639963
Other Study ID Numbers: MVMREF-001
First Posted: May 16, 2012    Key Record Dates
Last Update Posted: May 16, 2012
Last Verified: May 2012
Keywords provided by Dennis Niewoehner, Minnesota Veterans Medical Research and Education Foundation:
Chronic obstructive pulmonary disease
Chronic bronchitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchitis, Chronic
Respiratory Tract Diseases
Bronchial Diseases
Respiratory Tract Infections
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs